Where Te­va failed, Eli Lil­ly gained — mi­graine drug Em­gal­i­ty wins US ap­proval for episod­ic clus­ter headaches

It may be trail­ing be­hind its ri­vals in mi­graine sales, but Lil­ly’s Em­gal­i­ty has se­cured the FDA nod for episod­ic clus­ter headaches.

Em­gal­i­ty was the last in­jectable to win ap­proval for mi­graine pre­ven­tion last Sep­tem­ber, months af­ter Aimovig from Am­gen $AMGN  and No­var­tis $NVS, and Te­va’s {$TE­VA] Ajovy. All three form part of a fam­i­ly of drugs de­vel­oped to block cal­ci­tonin gene-re­lat­ed pep­tide (CGRP), a pro­tein as­so­ci­at­ed with the on­set of mi­graine pain. Each has demon­strat­ed a sig­nif­i­cant re­duc­tion in mi­graine fre­quen­cy in about half of pa­tients when test­ed in clin­i­cal stud­ies and is priced at $6,900 a year, or $575 per month. Tiny Alder’s $AL­DR CGRP is un­der FDA re­view.

In March, Em­gal­i­ty was grant­ed pri­or­i­ty re­view by the FDA for pre­ven­tion of episod­ic clus­ter headache in adults. The fol­low­ing month, Te­va aban­doned a late-stage tri­al test­ing Ajovy for episod­ic clus­ter headaches af­ter the drug failed to clear a fu­til­i­ty test, af­ter giv­ing up on a chron­ic clus­ter headache study last sum­mer. The Is­raeli drug­mak­er is still test­ing the drug for post-trau­mat­ic headaches.

Em­gal­i­ty was ap­proved on the ba­sis of da­ta from a 106-pa­tient place­bo-con­trolled study. In the tri­al, pa­tients on Em­gal­i­ty ex­pe­ri­enced an av­er­age of 8.7 few­er week­ly clus­ter headache at­tacks be­tween weeks 1 to 3 ver­sus 5.2 few­er week­ly at­tacks for pa­tients on place­bo (p=0.036). With Em­gal­i­ty, 71.4% of pa­tients had their week­ly clus­ter headache at­tacks cut in half or more from base­line at week 3 vs. 52.6% of pa­tients with place­bo (p=0.046).

“The op­por­tu­ni­ty in this pop­u­la­tion, which we es­ti­mate to be ~200,000 pa­tients in the US, could add to Lil­ly’s com­pet­i­tive ad­van­tage against Am­gen and Te­va,” Leerink an­a­lysts wrote in a note in April.

Af­flict­ed pa­tients ex­pe­ri­ence ex­cru­ci­at­ing headache at­tacks de­scribed some­times as “sui­cide headaches” be­tween 1-8 times per day, and these clus­ter cy­cles can last weeks or months and are usu­al­ly sep­a­rat­ed by headache-free re­mis­sion pe­ri­ods, which typ­i­cal­ly last months or years.

While the mi­graine dose is 120 mg, pa­tients pre­scribed Lil­ly’s $LLY Em­gal­i­ty for clus­ter headaches will be ad­min­is­tered a 300 mg dose at the on­set of a clus­ter pe­ri­od, fol­lowed by sub­cu­ta­neous in­jec­tions each month un­til the end of the pe­ri­od. The price per mg for Em­gal­i­ty re­mains the same, Lil­ly said.

In the first quar­ter of 2019, Aimovig gen­er­at­ed sales of $59 mil­lion, Ajovy brought in $20 mil­lion, while Em­gal­i­ty made $14 mil­lion.

The ap­proval comes as a wel­come re­lief for Lil­ly, which has suf­fered a string of set­backs in re­cent months — a late-stage fail­ure trig­gered the with­draw­al of its can­cer drug Lartru­vo, the US drug­mak­er rel­e­gat­ed two mid-stage drugs to the scrap heap, and Japan flagged safe­ty con­cerns as­so­ci­at­ed with its breast can­cer treat­ment, Verzenio.


Im­age: Kristof­fer Trip­plaar for SIPA AP

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.

Jim Mellon [via YouTube]

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

Earlier this year, an executive from Juvenescence-backed AgeX predicted the field of longevity will eventually “dwarf the dotcom boom.” Greg Bailey, the UK-based anti-aging biotech’s CEO, certainly hopes so.

On Monday, Juvenescence completed its $100 million Series B round of financing. The company is backed by British billionaire Jim Mellon — who wrote his 400-page guide to investing in the field of longevity shortly after launching the company in 2017. Bailey, who served as a board director for seven years at Medivation before Pfizer swallowed the biotech for $14 billion, is joined by Declan Doogan, an industry veteran with stints at Pfizer $PFE and Amarin $AMRN.

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.